Laser pico giây nd:yag 1064nm trong điều trị rám má

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Minh Châu Lê, Thái Vân Thanh Lê, Vi Anh Lê, Quốc Hưng Tạ

Ngôn ngữ: Vie

Ký hiệu phân loại: 616.5 Diseases of integument

Thông tin xuất bản: Tạp chí Y học Việt Nam 2023

Mô tả vật lý: 390-395

Bộ sưu tập: Metadata

ID: 407965

Thêm vào giỏ Liên kết toàn văn

Tóm tắt
Chủ đề

Đánh giá hiệu quả lâm sàng của Laser pico giây Nd:Yag 1064nm trong điều trị rám má. Phương pháp: Nghiên cứu mô tả hàng loạt ca, theo dõi dọc trên các bệnh nhân rám má được chỉ định điều trị bằng laser pico giây Nd:Yag 1064nm tại khoa Da Liễu - Thẩm mỹ da, Bệnh viện Đại học Y Dược TPHCM từ tháng 8/2021 đến tháng 8/2022. Kết quả: Tuổi trung bình của bệnh nhân là 44,9 ± 6,7
100% bệnh nhân là nữ
Đa số bệnh nhân đều không có tiền sử gia đình tăng sắc tố và không có tiền sử tăng sắc tố ở lần mang thai trước (hai tỉ lệ này đều ở mức 61,1%). Trong nghiên cứu, có 55,6% bệnh nhân mang khẩu trang thường xuyên và số lượng người dùng khẩu trang màu sáng ở mức 55,6% . Phân loại mức độ tăng sắc tố trước điều trị, trường hợp nhẹ chiếm 5,6%, trung bình chiếm 16,7%, nặng chiếm 22,2% và rất nặng chiếm 55,6%. Chỉ số L, b khi đo bằng Colorimeter tăng có giá trị thống kê qua từng lần điều trị (p<
0,05) nhưng chỉ số a không thay đổi có ý nghĩa thống kê . Ngoài ra, khi đánh giá hiệu quả điều trị bằng máy VISIA, các chỉ số về Spots, Brown Spots và Porphyrins cũng tăng có ý nghĩa thống kê với p<
0,05. Chỉ số về độ nặng và diện tích rám má (Melasma area and severity index_ MASI) cũng giảm có ý nghĩa thống kê sau từng lần điều trị với p<
0,001. Không có bệnh nhân nào không thấy cải thiện sau lần điều trị thứ 1. Điểm chất lượng cuộc sống bị chi phối bởi rám má (Melasma Quality of Life_MELASQoL) cũng giảm theo từng lần điều trị với p<
0,001. Có 50% bệnh nhân trong nghiên cứu không ghi nhận tác dụng phụ về mặt chủ quan lẫn khách quan. Tác dụng phụ chủ quan ghi nhận trong nghiên cứu là châm chích (33,3%) và ngứa (16,7%). Tác dụng phụ khách quan duy nhất được ghi nhận là hồng ban (50%). Kết luận: Laser pico giây Nd:Yag 1064nm có thể là phương pháp an toàn, hiệu quả để điều trị rám má., Tóm tắt tiếng anh, To assess the clinical efficacy of the 1064nm Nd:Yag picosecond laser in treating melasma. Methods: Descriptive study of a series of cases, longitudinal follow-up on melasma patients assigned to be treated with a 1064nm Nd:Yag picosecond laser at the Department of Dermatology - Skin Aesthetics, University of Medicine and Pharmacy Hospital in Ho Chi Minh City from August 2021 to August 2022. Results: The average age of the patients was 44.9 ± 6.7%
all patients were femal. The majority of patients (61.1%) had neither a family history of hyperpigmentation nor a history of hyperpigmentation during a previous pregnancy. In the study, 55.6% of patients regularly wore masks, and 55.6% wore masks with light colors. In terms of sunscreen use, only 55.6% of patients regularly applied sunscreen. In the group of patients who used sunscreen, 66.67 percent correctly applied the product. Before treatment, the classification of hyperpigmentation severity revealed that 5.6% of cases were mild, 16,7% were moderate, 22,2% were severe, and 55,6% were very severe. Index L, b, as measured by Colorimeter, increased statistically significant with each treatment (p<
0.05), whereas index a change was not statistically significant. In addition, the indices of Spots, Brown Spots, and Porphyrins increased statistically significantly with p<
0.05 when evaluating the effectiveness of VISIA treatment. The Melasma Area and Severity Index (MASI) decreased significantly with p<
0.001 following each treatment. No patient did not experience improvement following the initial treatment. With each treatment, the Melasma Quality of Life (MELASQoL) score decreased, with P<
0.001. 50% of participants in the study reported no subjective or objective adverse effects.

Tạo bộ sưu tập với mã QR